JP5849384B2 - Folic acid-containing beverage - Google Patents
Folic acid-containing beverage Download PDFInfo
- Publication number
- JP5849384B2 JP5849384B2 JP2010180664A JP2010180664A JP5849384B2 JP 5849384 B2 JP5849384 B2 JP 5849384B2 JP 2010180664 A JP2010180664 A JP 2010180664A JP 2010180664 A JP2010180664 A JP 2010180664A JP 5849384 B2 JP5849384 B2 JP 5849384B2
- Authority
- JP
- Japan
- Prior art keywords
- folic acid
- beverage
- calcium
- weight
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims description 147
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims description 75
- 235000019152 folic acid Nutrition 0.000 title claims description 75
- 229960000304 folic acid Drugs 0.000 title claims description 75
- 239000011724 folic acid Substances 0.000 title claims description 75
- 235000013361 beverage Nutrition 0.000 title claims description 52
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 26
- 235000010233 benzoic acid Nutrition 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 239000010949 copper Substances 0.000 claims description 14
- 229910052802 copper Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- 239000005711 Benzoic acid Substances 0.000 claims description 11
- 150000001559 benzoic acids Chemical class 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- 150000005846 sugar alcohols Chemical class 0.000 claims description 9
- 150000002739 metals Chemical class 0.000 claims description 8
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000008213 purified water Substances 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229960005069 calcium Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000013329 compounding Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 7
- 239000004299 sodium benzoate Substances 0.000 description 7
- 235000010234 sodium benzoate Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 125000003929 folic acid group Chemical group 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- -1 p-hydroxybenzoic acid ester Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 235000013921 calcium diglutamate Nutrition 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
Description
本発明は、葉酸及び安息香酸類を含有する飲料に関する。 The present invention relates to a beverage containing folic acid and benzoic acids.
葉酸は、ビタミンＢ群の一種であり、アミノ酸やタンパク質、赤血球や核酸の合成などに関与しており、生体にとって必要不可欠な栄養素である。葉酸に関して、近年特に注目されていることは、母体の妊娠時の葉酸欠乏により、神経管異常の新生児が生まれる確率が増えるが、葉酸の投与によりこれを予防できることである(非特許文献１参照)。実際に、米国疾病管理予防センター（ＣＤＣ）は、一日４００μｇの葉酸を摂取すれば、胎児の神経管閉鎖障害を７０％予防することができるという勧告を出している。しかしながら、妊娠時に必要とされる葉酸全てを、食事から摂取することは困難であることが多く、サプリメント等が使用されてきた。 Folic acid is a kind of vitamin B group, is involved in the synthesis of amino acids, proteins, erythrocytes and nucleic acids, and is an essential nutrient for living bodies. With regard to folic acid, what has attracted particular attention in recent years is that the probability of a newborn with an abnormal neural tube is born due to folic acid deficiency during pregnancy in the mother, but this can be prevented by administration of folic acid (see Non-Patent Document 1). . In fact, the US Centers for Disease Control and Prevention (CDC) has issued a recommendation that ingesting 400 μg folic acid a day can prevent fetal neural tube closure disorder by 70%. However, it is often difficult to take all folic acid required during pregnancy from diet, and supplements and the like have been used.
従来、サプリメント等として食事以外から葉酸を摂取する際、固形製剤が用いられることが多く、葉酸を配合した飲料はほとんど提供されていなかった。この理由の１つとしては、葉酸の水中における安定性の問題が考えられる。すなわち、葉酸は水中での安定性が悪く、特に飲料に適した酸性領域では安定性がより悪くなり、徐々に分解が起こる。しかしながら、服用の容易性から葉酸を配合した飲料が求められている。 Conventionally, when folic acid is ingested as a supplement from other than meals, solid preparations are often used, and beverages containing folic acid have hardly been provided. One possible reason for this is the problem of stability of folic acid in water. That is, folic acid has poor stability in water, and in the acidic region particularly suitable for beverages, the stability becomes worse and gradually decomposes. However, beverages containing folic acid have been demanded for ease of taking.
一方、飲料には防腐作用を期待して安息香酸又はその塩、パラベン等の安息香酸類を配合することが行われている。長期保存のためには、これら防腐剤の添加が必要である。 On the other hand, benzoic acids such as benzoic acid or a salt thereof and paraben are blended in beverages in anticipation of antiseptic action. Addition of these preservatives is necessary for long-term storage.
本発明者らは、葉酸を含有する飲料に安息香酸類を配合したところ、葉酸の安定性がさらに悪くなり、葉酸の分解が促進されることを見出した。 The present inventors have found that when benzoic acids are added to a beverage containing folic acid, the stability of folic acid is further deteriorated and the decomposition of folic acid is promoted.
従って、本発明は安息香酸類を配合した葉酸含有飲料において、葉酸の分解を抑制し安定化を図ることを課題とする。 Accordingly, an object of the present invention is to suppress the decomposition of folic acid and stabilize it in a folic acid-containing beverage containing benzoic acids.
本発明者らは、上記課題を解決すべく鋭意研究を重ねた結果、安息香酸類を配合した葉酸含有飲料にカルシウム、銅、亜鉛からなる群から選ばれる一種以上の金属の無機塩又は有機塩を配合することにより、安息香酸類を配合しない飲料と同等の葉酸含有量を維持できることを見出した。さらに糖アルコール又はトレハロースを配合すると、葉酸の分解をさらに抑制できることも見出し、本発明を完成するに至った。 As a result of intensive research to solve the above problems, the present inventors have added an inorganic salt or organic salt of one or more metals selected from the group consisting of calcium, copper, and zinc to a folic acid-containing beverage containing benzoic acids. It has been found that by blending, the folic acid content equivalent to that of a beverage not containing benzoic acids can be maintained. Furthermore, when sugar alcohol or trehalose was mix | blended, it discovered that decomposition | disassembly of folic acid could be suppressed further and came to complete this invention.
すなわち、本発明は
（１）ａ）葉酸、ｂ）安息香酸類、並びに、ｃ）カルシウム、銅、及び亜鉛からなる群から選ばれる一種以上の金属の無機塩又は有機塩、を配合することを特徴とする飲料。
（２）安息香酸類が安息香酸又は安息香酸の塩である（１）に記載の飲料。
（３）さらに、糖アルコール又はトレハロースを配合することを特徴とする（１）又は（２）に記載の飲料。
（４）葉酸及び安息香酸類を含有する飲料に、カルシウム、銅、及び亜鉛からなる群から選ばれる一種以上の金属の無機塩又は有機塩を配合することを特徴とする、飲料中の葉酸の安定化方法。
（５）さらに、糖アルコール又はトレハロースを配合することを特徴とする（４）に記載の飲料中の葉酸の安定化方法。
である。
That is, the present invention is characterized by blending (1) a) folic acid, b) benzoic acids, and c) one or more inorganic or organic salts of metals selected from the group consisting of calcium, copper, and zinc. And drink.
(2) The beverage according to (1), wherein the benzoic acid is benzoic acid or a salt of benzoic acid.
(3) The beverage according to (1) or (2), further comprising sugar alcohol or trehalose.
(4) Stabilization of folic acid in beverages, characterized by blending a beverage containing folic acid and benzoic acids with one or more inorganic or organic salts of metals selected from the group consisting of calcium, copper, and zinc Method.
(5) The method for stabilizing folic acid in a beverage according to (4), further comprising sugar alcohol or trehalose.
It is.
本発明により、安息香酸類を配合した葉酸含有飲料中の葉酸の安定化を図ることができる。 According to the present invention, stabilization of folic acid in a folic acid-containing beverage containing benzoic acids can be achieved.
本発明におけるカルシウム、銅、及び亜鉛からなる群から選ばれる一種以上の金属の無機塩としては、塩化カルシウム、リン酸二水素カルシウム、リン酸三カルシウム、硫酸銅、硫酸亜鉛等が挙げられ、有機塩としては、乳酸カルシウム、グルコン酸カルシウム、クエン酸カルシウム、グルタミン酸カルシウム、パントテン酸カルシウム、グルコン酸銅、グルコン酸亜鉛等が挙げられるが、これらに限定されない。また、これらは水和物として存在することもあるが、その水和物を使用しても構わない。該金属の無機塩又は有機塩の配合量は、本発明の効果を十分に奏するために以下の配合量とすることが好ましい。すなわち、葉酸１重量部に対して、カルシウム換算で１１０重量部以上、より好ましくは３５０重量部以上、亜鉛換算で１１０重量部以上、銅換算で２５重量部以上、より好ましくは６０重量部以上である。 Examples of the inorganic salt of one or more metals selected from the group consisting of calcium, copper, and zinc in the present invention include calcium chloride, calcium dihydrogen phosphate, tricalcium phosphate, copper sulfate, zinc sulfate, and the like. Examples of the salt include, but are not limited to, calcium lactate, calcium gluconate, calcium citrate, calcium glutamate, calcium pantothenate, copper gluconate, and zinc gluconate. Moreover, although these may exist as a hydrate, you may use the hydrate. The compounding amount of the metal inorganic salt or organic salt is preferably set to the following compounding amount in order to sufficiently achieve the effects of the present invention. That is, with respect to 1 part by weight of folic acid, 110 parts by weight or more in terms of calcium, more preferably 350 parts by weight or more, 110 parts by weight or more in terms of zinc, 25 parts by weight or more in terms of copper, more preferably 60 parts by weight or more. is there.
本発明における「安息香酸類」には、安息香酸又はその塩、さらには安息香酸構造を有する物質も含まれる。安息香酸の塩としては、安息香酸ナトリウム等が挙げられる。安息香酸構造を有する物質としては、パラオキシ安息香酸エステル、パラアミノ安息香酸が挙げられる。 The “benzoic acid” in the present invention includes benzoic acid or a salt thereof, and further a substance having a benzoic acid structure. Examples of the salt of benzoic acid include sodium benzoate. Examples of the substance having a benzoic acid structure include p-hydroxybenzoic acid ester and p-aminobenzoic acid.
本発明における「糖アルコール」には、エリスリトール、キシリトール、マルチトール、イノシトール、ソルビトール、マンニトール、マルチトール等を使用することができる。糖アルコールの配合量は、本発明の効果を十分に奏するために葉酸１重量部に対して、４３０００重量部以上であることが好ましい。また、トレハロースも葉酸１重量部に対して、４３０００重量部以上配合することが好ましい。 As the “sugar alcohol” in the present invention, erythritol, xylitol, maltitol, inositol, sorbitol, mannitol, maltitol and the like can be used. The amount of the sugar alcohol is preferably 43,000 parts by weight or more with respect to 1 part by weight of folic acid in order to sufficiently achieve the effects of the present invention. Trehalose is also preferably added in an amount of 43,000 parts by weight or more based on 1 part by weight of folic acid.
本発明では、上記「金属の無機塩又は有機塩」と糖アルコール又はトレハロースを同時に配合することで、葉酸の安定化をさらに図ることができるため好ましい。 In the present invention, folic acid can be further stabilized by simultaneously blending the above-mentioned “metal inorganic salt or organic salt” with sugar alcohol or trehalose, which is preferable.
本発明において「葉酸の安定化」とは、飲料中での経時的な葉酸の分解を抑制することである。 In the present invention, “stabilization of folic acid” is to suppress degradation of folic acid over time in a beverage.
本発明の飲料の好ましいｐＨは２．５以上である。ｐＨが２．５未満であると酸味が強すぎて服用性の点で好ましくないからである。なお、本発明を用いることで、低ｐＨにおいても飲料中の葉酸を安定化させることができるようになったので、ｐＨが２．５を下回る範囲で本発明を実施することを妨げるものではない。ｐＨの調整には、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸及びコハク酸などの有機酸、又はこれら有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を用いることができる。 The preferred pH of the beverage of the present invention is 2.5 or higher. This is because if the pH is less than 2.5, the acidity is too strong, which is not preferable in terms of ingestion. In addition, since it became possible to stabilize folic acid in beverages even at low pH by using the present invention, it does not prevent the present invention from being carried out in a range where the pH is below 2.5. . For adjusting the pH, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid, or salts of these organic acids, inorganic acids such as phosphoric acid and hydrochloric acid, inorganic acids such as sodium hydroxide, etc. A base can be used.
本発明における「飲料」とは、内服することができる液体であれば特に制限はなく、飲料として必要とされる甘味料等を配合していないものも含まれる。具体的には、例えば内服液剤、ドリンク剤等の医薬品及び指定医薬部外品の他、栄養機能性食品、特定保健用食品等の食品領域における各種飲料が挙げられる。 The “beverage” in the present invention is not particularly limited as long as it is a liquid that can be taken internally, and includes those that do not contain a sweetener or the like required as a beverage. Specifically, for example, in addition to pharmaceuticals such as internal liquids and drinks and designated quasi-drugs, various beverages in food areas such as nutritional functional foods and foods for specified health use can be mentioned.
本発明の飲料には、ビタミン類、ミネラル類、アミノ酸類、生薬、生薬抽出物、カフェインなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤、甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合することもできる。 In the beverage of the present invention, vitamins, minerals, amino acids, herbal medicines, herbal extracts, caffeine, and the like can be appropriately blended as long as the effects of the present invention are not impaired. In addition, additives such as antioxidants, colorants, fragrances, flavoring agents, surfactants, solubilizers, preservatives, sweeteners, and the like are appropriately blended as necessary so long as the effects of the invention are not impaired. You can also.
本発明の飲料を調製する方法は特に限定されるものではない。通常、各成分を適量の精製水で溶解した後、ｐＨを調整し、更に精製水を加えて容量調整し、必要に応じて濾過、滅菌処理を施すことにより、葉酸含有飲料として提供することができる。 The method for preparing the beverage of the present invention is not particularly limited. Usually, after each component is dissolved in an appropriate amount of purified water, the pH is adjusted, and the volume is further adjusted by adding purified water, followed by filtration and sterilization as necessary to provide a folic acid-containing beverage. it can.
以下に、実施例、比較例及び試験例を挙げ、本発明をさらに詳細に説明するが、本発明はこれらの実施例等に何ら限定されるものではない。下記において、ｐＨの調整には塩酸又は水酸化ナトリウムを用いている。なお、実施例で用いたグルコン酸カルシウムは１水和物であり、グルコン酸亜鉛は３水和物である。 Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples, and Test Examples, but the present invention is not limited to these Examples. In the following, hydrochloric acid or sodium hydroxide is used for pH adjustment. In addition, the calcium gluconate used in the Example is a monohydrate, and zinc gluconate is a trihydrate.
製造例１
葉酸４０ｍｇとクエン酸ナトリウム１０００ｍｇを精製水を加えて溶解し、５０ｍＬとした後、この溶液から１０ｍＬを計りとり、精製水を加えて全量１０００ｍＬとし、さらにこの溶液から５０ｍＬを計りとった。
Production Example 1
40 mg of folic acid and 1000 mg of sodium citrate were dissolved in purified water to make 50 mL, 10 mL was measured from this solution, purified water was added to make a total volume of 1000 mL, and 50 mL was further measured from this solution.
製造例２
クエン酸ナトリウム４．７０４ｇ、クエン酸４．８００ｇ、及び安息香酸ナトリウム２．８８ｇを精製水を加えて溶かし、精製水を加えて全量１２００ｍＬとした溶液から１２５ｍＬを計りとった。
Production Example 2
4.704 g of sodium citrate, 4.800 g of citric acid and 2.88 g of sodium benzoate were dissolved by adding purified water, and 125 mL was measured from the solution made up to a total volume of 1200 mL by adding purified water.
実施例１−６、参考例１、及び比較例３−５
製造例１及び２で計りとったそれぞれの溶液を混合し、さらに表１−１又は１−２記載の濃度になるように金属の無機塩又は有機塩、糖アルコールを加え、精製水で４５０ｍＬに調整した後、ｐＨを４．５に調整し、更に精製水を加えて全量を５００ｍＬとし、再度ｐＨを４．５に調整して実施例１−６、参考例１、及び比較例３−５の葉酸含有飲料を製造した。なお、表１−１及び１−２の数値は各飲料１００ｍＬ中の成分の配合量を示している。
Example 1-6, Reference Example 1, and Comparative Example 3-5
Each solution measured in Production Examples 1 and 2 is mixed, and further added with a metal inorganic salt or organic salt and sugar alcohol so as to have a concentration described in Table 1-1 or 1-2, and purified to 450 mL with purified water. After the adjustment, the pH was adjusted to 4.5, further purified water was added to make the total volume 500 mL, and the pH was adjusted to 4.5 again to obtain Example 1-6, Reference Example 1, and Comparative Example 3-5. A folic acid-containing beverage was produced. In addition, the numerical value of Table 1-1 and 1-2 has shown the compounding quantity of the component in 100 mL of each drink.
比較例１
製造例１で計りとった溶液に、クエン酸ナトリウム０．４９０ｇ、クエン酸０．５００ｇを加えて溶かし、精製水で４５０ｍＬに調整した後、ｐＨを４．５に調整し、更に精製水を加えて全量を５００ｍＬとし、再度ｐＨを４．５に調整して比較例１の葉酸含有飲料を製造した。上記と同様に表１−２の数値は比較例１の飲料１００ｍＬ中の配合量を示している。
Comparative Example 1
To the solution measured in Production Example 1, 0.490 g of sodium citrate and 0.500 g of citric acid are added and dissolved. After adjusting to 450 mL with purified water, the pH is adjusted to 4.5, and further purified water is added. The total amount was adjusted to 500 mL, and the pH was adjusted to 4.5 again to produce a folic acid-containing beverage of Comparative Example 1. Similarly to the above, the numerical values in Table 1-2 indicate the blending amount in 100 mL of beverage of Comparative Example 1.
比較例２
製造例１及び２で計りとったそれぞれの溶液を混合し、精製水で４５０ｍＬに調整した後、ｐＨを４．５に調整し、更に精製水を加えて全量を５００ｍＬとし、再度ｐＨを４．５に調整して比較例２の葉酸含有飲料を製造した。上記と同様に表１−２の数値は比較例２の飲料１００ｍＬ中の配合量を示している。
Comparative Example 2
The respective solutions measured in Production Examples 1 and 2 were mixed, adjusted to 450 mL with purified water, adjusted to pH 4.5, and further purified water was added to bring the total volume to 500 mL. The folic acid-containing beverage of Comparative Example 2 was prepared by adjusting to 5. The numerical value of Table 1-2 has shown the compounding quantity in 100 mL of drinks of the comparative example 2 similarly to the above.
試験例１
実施例１−６、参考例１及び比較例１−５の飲料から５０ｍＬをガラス瓶に充填しキャップを施して、６５℃の恒温槽中で７日間保存し、飲料中の葉酸含有量をＨＰＬＣで測定した。葉酸を溶解させた直後の飲料中の葉酸含有量に対して、６５℃７日間保存後の葉酸含有量を計算した。結果を表１−１及び１−２に示す。
Test example 1
A glass bottle was filled with 50 mL of the beverage of Example 1-6, Reference Example 1 and Comparative Example 1-5, capped, and stored in a thermostatic bath at 65 ° C. for 7 days, and the folic acid content in the beverage was measured by HPLC. It was measured. The folic acid content after storage at 65 ° C. for 7 days was calculated with respect to the folic acid content in the beverage immediately after folic acid was dissolved. The results are shown in Tables 1-1 and 1-2.
比較例１、２の結果から、安息香酸ナトリウムを配合することで６５℃７日間保存後の葉酸含有量の対直後値（％）が低くなることがわかった。しかし、カルシウム、銅、亜鉛を用いた実施例１−５では、安息香酸ナトリウムを配合しているにも関わらず、葉酸含有量の対直後値が比較例１と同程度に維持されていることがわかった。実施例６ではさらにソルビトールを配合することで、比較例１以上の葉酸含有量の対直後値が得られることがわかった。ソルビトールのみを配合した参考例１においても、実施例１−５と同等程度の葉酸含有量の対直後値が得られた。 From the results of Comparative Examples 1 and 2, it was found that by adding sodium benzoate, the folic acid content immediately after storage at 65 ° C. for 7 days (%) was lowered. However, in Example 1-5 using calcium, copper, and zinc, the value immediately after the folic acid content is maintained at the same level as in Comparative Example 1 despite the addition of sodium benzoate. I understood. In Example 6, it was found that the value immediately after the folic acid content of Comparative Example 1 or more was obtained by further blending sorbitol. Also in Reference Example 1 in which only sorbitol was blended, a value immediately after the folic acid content comparable to that of Example 1-5 was obtained.
なお、比較例３−５に示すとおり、カルシウム、銅、亜鉛以外の金属種を用いた場合、葉酸含有量の対直後値は比較例２に比べて低いものであった。すなわち、全ての金属種で飲料中の葉酸の安定性が確保出来るわけではないことがわかった。 As shown in Comparative Example 3-5, when a metal species other than calcium, copper, and zinc was used, the value immediately after the folic acid content was lower than that of Comparative Example 2. That is, it was found that not all metal species can secure the stability of folic acid in beverages.
製造例３
葉酸８０ｍｇとクエン酸ナトリウム２０００ｍｇを精製水を加えて溶解し、５０ｍＬとした後、この溶液から３０ｍＬを計りとり、精製水を加えて全量１０００ｍＬとし、さらにこの溶液から５０ｍＬを計りとった。
Production Example 3
80 mg of folic acid and 2000 mg of sodium citrate were dissolved in purified water to make 50 mL, then 30 mL was measured from this solution, purified water was added to make a total volume of 1000 mL, and 50 mL was further measured from this solution.
製造例４
クエン酸ナトリウム１９．６０ｇ、クエン酸２０．００ｇ、及び安息香酸ナトリウム１２．００ｇを精製水を加えて溶かし、精製水を加えて全量２０００ｍＬとした溶液から３００ｍＬを計りとった。
Production Example 4
19.60 g of sodium citrate, 20.00 g of citric acid, and 12.00 g of sodium benzoate were dissolved by adding purified water, and 300 mL was measured from the solution made up to 2000 mL by adding purified water.
実施例７−１２
製造例３及び４で計りとったそれぞれの溶液を混合し、さらに表２−１又は２−２記載の濃度になるように金属の有機塩を加え、精製水で２５００ｍＬに調整した後、ｐＨを３．５又は５．５に調整し、更に精製水を加えて全量を３０００ｍＬとし、再度ｐＨを３．５又は５．５に調整して実施例７−１２の葉酸含有飲料を製造した。なお、表２−１及び２−２の数値は各飲料１００ｍＬ中の成分の配合量を示している。
Examples 7-12
After mixing the respective solutions measured in Production Examples 3 and 4, further adding a metal organic salt so as to have the concentration described in Table 2-1 or 2-2, adjusting to 2500 mL with purified water, and then adjusting the pH. The folic acid-containing beverage of Example 7-12 was prepared by adjusting to 3.5 or 5.5, further adding purified water to a total volume of 3000 mL, and again adjusting the pH to 3.5 or 5.5. In addition, the numerical value of Table 2-1 and 2-2 has shown the compounding quantity of the component in 100 mL of each drink.
比較例６−７
製造例３及び４で計りとったそれぞれの溶液を混合し、精製水で２５００ｍＬに調整した後、ｐＨを３．５又は５．５に調整し、更に精製水を加えて全量を３０００ｍＬとし、再度ｐＨを３．５又は５．５に調整して比較例６−７の葉酸含有飲料を製造した。上記と同様に表２−１及び２−２の数値は各飲料１００ｍＬ中の成分の配合量を示している。
Comparative Example 6-7
After mixing each solution measured in Production Examples 3 and 4 and adjusting to 2500 mL with purified water, the pH is adjusted to 3.5 or 5.5, and further purified water is added to make the total volume 3000 mL. The folic acid-containing beverage of Comparative Example 6-7 was produced by adjusting the pH to 3.5 or 5.5. Similarly to the above, the numerical values in Tables 2-1 and 2-2 indicate the compounding amounts of the components in 100 mL of each beverage.
試験例２
実施例７−１２、及び比較例６−７の飲料から５０ｍＬをガラス瓶に充填しキャップを施してさらに８０℃恒温槽中で２５分間の殺菌を施した。これらを４０℃の恒温槽中で３ヶ月間保存し、飲料中の葉酸含有量をＨＰＬＣで測定した。葉酸を溶解させた直後の飲料中の葉酸含有量に対して、４０℃３ヶ月間保存後の飲料中の葉酸含有量を計算した。結果を表２−１及び２−２に示す。
Test example 2
A glass bottle was filled with 50 mL of the beverages of Examples 7-12 and Comparative Example 6-7, capped, and further sterilized for 25 minutes in an 80 ° C. constant temperature bath. These were stored in a constant temperature bath at 40 ° C. for 3 months, and the folic acid content in the beverage was measured by HPLC. The folic acid content in the beverage after storage at 40 ° C. for 3 months was calculated with respect to the folic acid content in the beverage immediately after folic acid was dissolved. The results are shown in Tables 2-1 and 2-2.
ｐＨ３．５及びｐＨ５．５の飲料においても、安息香酸ナトリウムによる葉酸含有量の低下がカルシウム、銅、亜鉛を用いた実施例７−１２では、抑制されていることがわかった。 Also in the drink of pH 3.5 and pH 5.5, it turned out that the fall of the folic acid content by sodium benzoate is suppressed in Examples 7-12 using calcium, copper, and zinc.
実施例１３−１５
製造例１及び２で計りとったそれぞれの溶液を混合し、さらに表３記載の濃度になるようにグルコン酸カルシウム、トレハロースを加え、精製水で４５０ｍＬに調整した後、ｐＨを２．５に調整し、更に精製水を加えて全量を５００ｍＬとし、再度ｐＨを２．５に調整して実施例１３−１５の葉酸含有飲料を製造した。なお、表３の数値は各飲料１００ｍＬ中の成分の配合量を示している。
Examples 13-15
Mix each solution measured in Production Example 1 and 2, add calcium gluconate and trehalose to the concentration shown in Table 3, adjust to 450 mL with purified water, then adjust pH to 2.5 Further, purified water was added to make the total amount 500 mL, and the pH was adjusted to 2.5 again to produce a folic acid-containing beverage of Example 13-15. In addition, the numerical value of Table 3 has shown the compounding quantity of the component in 100 mL of each drink.
比較例８
製造例１及び２で計りとったそれぞれの溶液を混合し、精製水で４５０ｍＬに調整した後、ｐＨを２．５に調整し、更に精製水を加えて全量を５００ｍＬとし、再度ｐＨを２．５に調整して比較例８の葉酸含有飲料を製造した。上記と同様に表３の数値は比較例８の飲料１００ｍＬ中の配合量を示している。
Comparative Example 8
The respective solutions measured in Production Examples 1 and 2 were mixed, adjusted to 450 mL with purified water, adjusted to pH 2.5, and further purified water was added to bring the total volume to 500 mL. The folic acid-containing beverage of Comparative Example 8 was prepared by adjusting to 5. The numerical value of Table 3 has shown the compounding quantity in 100 mL of drinks of the comparative example 8 similarly to the above.
試験例３
実施例１３−１５、及び比較例８の飲料から５０ｍＬをガラス瓶に充填しキャップを施して、６５℃の恒温槽中で７日間保存し、飲料中の葉酸含有量をＨＰＬＣで測定した。葉酸を溶解させた直後の飲料中の葉酸含有量に対して、６５℃７日間保存後の葉酸含有量を計算した。結果を表３に示す。
Test example 3
A glass bottle was filled with 50 mL from the beverages of Examples 13-15 and Comparative Example 8, capped, and stored in a thermostatic bath at 65 ° C. for 7 days, and the folic acid content in the beverage was measured by HPLC. The folic acid content after storage at 65 ° C. for 7 days was calculated with respect to the folic acid content in the beverage immediately after folic acid was dissolved. The results are shown in Table 3.
ｐＨ２．５の飲料においても、安息香酸ナトリウムによる葉酸含有量の低下がカルシウムを用いた実施例１３−１５では、抑制されていることがわかった。また、実施例１３と１４の比較により、カルシウムの配合量が多いほど葉酸の安定化効果が大きいこと、実施例１５より、トレハロースをさらに配合することで葉酸の安定化効果が大きくなること、がわかった。 Also in the drink of pH2.5, it turned out that the fall of the folic acid content by sodium benzoate is suppressed in Examples 13-15 using calcium. Further, according to comparison between Examples 13 and 14, the greater the amount of calcium added, the greater the effect of stabilizing folic acid. From Example 15, the effect of stabilizing folic acid is further increased by further adding trehalose. all right.
以上の結果より、葉酸を含有する飲料において、カルシウム、銅、及び亜鉛からなる群から選ばれる一種以上の金属の無機塩又は有機塩を配合することにより、安息香酸類による葉酸の分解を抑制し安定化を図ることができた。 From the above results, in beverages containing folic acid, by adding one or more inorganic or organic salts of metals selected from the group consisting of calcium, copper, and zinc, the decomposition of folic acid by benzoic acids is suppressed and stabilized. We were able to plan.
本発明により、長期に保存可能な葉酸含有飲料を製造することが可能となったので、商品性の高い葉酸含有飲料を医薬品、指定医薬部外品及び食品の分野において提供することが期待される。 Since the present invention makes it possible to produce a folic acid-containing beverage that can be stored for a long period of time, it is expected to provide a highly commercial folic acid-containing beverage in the fields of pharmaceuticals, designated quasi-drugs and foods. .
Claims (5)
ｃ）成分の配合量が、葉酸１重量部に対してカルシウム換算で１１０重量部以上、
亜鉛換算で１１０重量部以上、銅換算で６０重量部以上であることを特徴とする飲料。 a) folic acid, b) benzoic acids, and c) one or more inorganic or organic salts of metals selected from the group consisting of calcium, copper, and zinc,
c) The amount of the component is 110 parts by weight or more in terms of calcium with respect to 1 part by weight of folic acid,
A beverage characterized by being 110 parts by weight or more in terms of zinc and 60 parts by weight or more in terms of copper.
カルシウム、銅、及び亜鉛からなる群から選ばれる一種以上の金属の無機塩又は有機塩の配合量が、葉酸１重量部に対してカルシウム換算で１１０重量部以上、
亜鉛換算で１１０重量部以上、銅換算で６０重量部以上であることを特徴とする、飲料中の葉酸の安定化方法。 In a beverage containing folic acid and benzoic acid, an inorganic salt or organic salt of one or more metals selected from the group consisting of calcium, copper, and zinc are blended,
The amount of the inorganic or organic salt of one or more metals selected from the group consisting of calcium, copper, and zinc is 110 parts by weight or more in terms of calcium with respect to 1 part by weight of folic acid,
A method for stabilizing folic acid in beverages, characterized in that it is 110 parts by weight or more in terms of zinc and 60 parts by weight or more in terms of copper.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010180664A JP5849384B2 (en) | 2009-08-12 | 2010-08-12 | Folic acid-containing beverage |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009187131 | 2009-08-12 | ||
| JP2009187131 | 2009-08-12 | ||
| JP2010180664A JP5849384B2 (en) | 2009-08-12 | 2010-08-12 | Folic acid-containing beverage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011055828A JP2011055828A (en) | 2011-03-24 |
| JP5849384B2 true JP5849384B2 (en) | 2016-01-27 |
Family
ID=43944219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010180664A Active JP5849384B2 (en) | 2009-08-12 | 2010-08-12 | Folic acid-containing beverage |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5849384B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6862108B2 (en) * | 2016-06-30 | 2021-04-21 | ハウスウェルネスフーズ株式会社 | Folic acid-containing acidic composition with excellent folic acid stability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3773390D1 (en) * | 1987-12-07 | 1991-10-31 | Holger Blum | STABILIZED AQUEOUS FOLIC ACID PREPARATION. |
| JP3492365B2 (en) * | 1992-11-19 | 2004-02-03 | ザ、プロクター、エンド、ギャンブル、カンパニー | A method for enhancing the bioavailability of .BETA.-carotene |
| US6352713B1 (en) * | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
| JP2002097141A (en) * | 2000-09-19 | 2002-04-02 | Nikken Chem Co Ltd | Aqueous solution of vitamin b |
| JP4091860B2 (en) * | 2002-01-31 | 2008-05-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Drugs for the treatment of neurological disorders |
| US20090186127A1 (en) * | 2004-12-15 | 2009-07-23 | Krumhar Kim C | Energy drink compositions |
| JP4545632B2 (en) * | 2005-04-25 | 2010-09-15 | 株式会社 伊藤園 | Folic acid-containing composition and method for stabilizing folic acid |
| JP2008127371A (en) * | 2006-11-24 | 2008-06-05 | Kowa Co | Stable internal liquid medicine composition |
-
2010
- 2010-08-12 JP JP2010180664A patent/JP5849384B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011055828A (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201204268A (en) | Substantially clear nutritional liquids comprising calcium HMB and soluble protein | |
| JP5421769B2 (en) | Liquid nutrition composition containing sodium in high concentration and method for producing the same | |
| WO2007108712A1 (en) | Kit and method for treating or preventing anemia caused by iron deficiency | |
| JP5849384B2 (en) | Folic acid-containing beverage | |
| US20080124439A1 (en) | Nutritional supplement composition comprising creatine and method for making the same | |
| JP6762782B2 (en) | An acidic composition with excellent stability of the folic acid contained | |
| JP6672599B2 (en) | Beverage | |
| JP5123574B2 (en) | Hyaluronic acid production enhancer | |
| JP6308210B2 (en) | Aqueous liquid composition containing L-histidine in high concentration | |
| US20130302448A1 (en) | Phytin aqueous solution and use of said solution for the preparation of a liquid nutritional supplement or a cosmetic composition | |
| JP5682118B2 (en) | Folic acid-containing beverage | |
| JP4645841B2 (en) | Royal jelly-containing beverage composition | |
| JP2002097141A (en) | Aqueous solution of vitamin b | |
| JP4645842B2 (en) | Royal jelly-containing beverage composition | |
| TW201726126A (en) | Liquid agent containing biotin | |
| JP4765901B2 (en) | Royal jelly-containing beverage composition | |
| JP2010095474A (en) | Calcium absorption-promoting composition and calcium absorption-promoting food and drink | |
| JP4697123B2 (en) | Royal jelly-containing beverage composition | |
| JP2017193532A (en) | Composition for improving bone density, food composition for improving bone density, composition for improving liver function, and food composition for improving liver function | |
| JP5997425B2 (en) | Ornithine-containing composition | |
| WO2022107673A1 (en) | Beverage containing placenta and iron | |
| JP2022080208A (en) | Formulation for intravenous infusion of zinc | |
| JPH11243914A (en) | Food or beverage promoting calcium absorption | |
| JP4900205B2 (en) | Royal jelly-containing beverage composition | |
| JP2022081425A (en) | Iron compound-containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130730 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141002 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150512 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151117 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5849384 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |